- The FDA has cleared Poseida Therapeutics Inc PSTX Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple myeloma.
- The Phase 1 study will assess safety, tolerability, and response. The study protocol allows for exploration of additional dosing regimens, including re-dosing, once initial safety has been established.
- Poseida is actively focused on opening clinical sites to begin dosing later this year.
- Related content: Benzinga's Full FDA Calendar
- Price Action: PSTX stock is up 5% at $10.40 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsmultiple myelomaPhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
